Ignyta Boosts Leadership Capacity with Appointment of Bernard Parker as Chief Commercial Officer

SAN DIEGO–(BUSINESS WIRE)–Ignyta, Inc. (Nasdaq: RXDX), a precision oncology
biotechnology company, announced today that Bernard Parker has been
appointed to the newly-created role of Chief Commercial Officer.

“We are excited to expand our leadership capacity at Ignyta with the
addition of Bernard to our executive team,” said Jonathan Lim, M.D.,
Chairman and CEO of Ignyta. “Bernard brings a wealth of commercial
experience to Ignyta from a variety of senior roles spanning sales,
marketing, reimbursement, global brand management and regional business
unit leadership at several leading pharmaceutical companies. His broad,
international expertise and demonstrated ability to execute will be
valuable to us as we prepare to transition into a commercial stage
company with STARTRK-2, a potential registration-enabling study for
entrectinib, a key step forward in our quest to provide new treatment
options for cancer patients.”

Mr. Parker was most recently Head of the EMEA Pharmaceuticals Franchise
for the Alcon division of Novartis, a position he held since 2013. In
this role, he was responsible for all commercial initiatives for Alcon’s
ophthalmic pharmaceuticals and over-the-counter business. Prior to
Alcon, Mr. Parker was Global Brand Director, Biopharmaceuticals
Portfolio for the Sandoz division of Novartis, a position he held from
2009 to 2013. At Sandoz, Mr. Parker led all commercial and lifecycle
management activities for the oncology biosimilars granulocyte
colony-stimulating factor (G-CSF) portfolio, including the launch of
Zarzio®, the top prescribed biosimilar G-CSF product in the
world. From 2008 to 2009, Mr. Parker was a management consultant at Bain
& Company, working on growth strategy and profit improvement projects
across a variety of industries. Prior to Bain, Mr. Parker gained
experience in the U.S. in various marketing and sales roles at Amgen,
Pfizer and Parke-Davis, where his work spanned the oncology,
cardiovascular, diabetes and neurology therapeutic areas and included
assisting with the launch of Lipitor® as a sales
representative. Bernard holds an M.B.A. from Harvard Business School and
a B.A. in biology magna cum laude from Hampton University, where
he was a President’s Eminent Scholar and was awarded a biomedical
research fellowship funded by the National Institutes of Health to
conduct research in cell biology.

On July 22, 2015, Mr. Parker will receive an inducement stock option
award under Ignyta’s 2015 Employment Inducement Incentive Award Plan,
which was adopted July 17, 2015 and provides for the granting of equity
awards to new employees of Ignyta. The inducement award consists of an
option to purchase an aggregate of 200,000 shares of Ignyta common
stock. The option has a ten-year term and an exercise price equal to the
closing price per share of Ignyta’s common stock on the Nasdaq Capital
Market on the date of grant. The option vests over a four-year period,
with 25% of the option vesting on the first anniversary of the date of
hire and the remainder vesting in equal monthly installments over the
three years thereafter. The award was approved by the compensation
committee of Ignyta’s board of directors and was granted as an
inducement material to Mr. Parker entering into employment with Ignyta
in accordance with Nasdaq Marketplace Rule 5635(c)(4).

About Ignyta, Inc.

Ignyta, Inc., located in San Diego, California, is a precision oncology
biotechnology company pursuing an integrated therapeutic (Rx) and
companion diagnostic (Dx) strategy for treating cancer patients. The
company’s goal with this Rx/Dx approach is to discover, develop and
commercialize new drugs that target activated cancer genes and pathways
for the customized treatment of cancer, as well as novel
chemotherapeutics that can potentially provide additional benefit to
cancer patients. It aims to achieve this goal by pairing its product
candidates with biomarker-based companion diagnostics that are designed
to identify, at the molecular level, the patients who are most likely to
benefit from the precisely targeted drugs the company develops. For more
information, please visit: www.ignyta.com.

Forward-Looking Statements

This press release contains forward-looking statements about Ignyta as
that term is defined in Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Statements in this
press release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other things,
references to the potential for Ignyta to provide new treatment options
for patients with its proprietary oncology drug development programs.
Actual results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among others,
the potential for results of current or future clinical trials of
entrectinib or other product candidates to differ from preliminary or
expected results; the inherent uncertainties associated with developing
new products or technologies and operating as a development stage
company; Ignyta’s ability to develop, complete preclinical studies and
clinical trials for, obtain approvals for and commercialize any of its
product candidates; changes in Ignyta’s plans to develop and
commercialize its product candidates; the potential for the company to
fail to maintain the CLIA registration of its diagnostic laboratory or
to fail to achieve full CLIA accreditation of such laboratory; Ignyta’s
ability to raise any additional funding it will need to continue to
pursue its business and product development plans; regulatory
developments in the United States and foreign countries; Ignyta’s
ability to obtain and maintain intellectual property protection for its
product candidates; the risk that orphan drug exclusivity may not be
maintained or may not effectively protect a product from competition;
the loss of key scientific or management personnel; competition in the
industry in which Ignyta operates; and market conditions. These
forward-looking statements are made as of the date of this press
release, and Ignyta assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could differ
from those projected in the forward-looking statements. Investors should
consult all of the information set forth herein and should also refer to
the risk factor disclosure set forth in the reports and other documents
the company files with the SEC available at www.sec.gov,
including without limitation Ignyta’s Annual Report on Form 10-K for the
year ended December 31, 2014 and subsequent Quarterly Reports on Form


Ignyta, Inc.
Jacob Chacko, M.D.

Powered by WPeMatico